Business
SynAct Pharma lays out dual strategy for resolution therapy at capital markets day
SynAct Pharma lays out dual strategy for resolution therapy at capital markets
About this update from Synact Pharma Ab
At the recent capital markets day, SynAct Pharma presented its strategic roadmap for resomelagon, detailing a dual strategy targeting rheumatoid arthritis and respiratory infections. Supported by external clinical expertise and a robust financial position, management highlighted the candidate's potential to redefine inflammation treatment through resolution therapy. With the phase IIb ADVANCE study nearing its primary readout in June, the company remains focused on data-driven business development. BioStock contacted CEO Jeppe Øvlesen for a comment. Read the full interview at biostock.se: SynAct Pharma lays out dual strategy for resolution therapy at capital markets day This is a press release from BioStock - Connecting Innovation & Capital . https://www.biostock.se/ Follow BioStock Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter Follow BioStock on social media: LinkedIn and Facebook! About BioStock BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments. BioStock – Connecting Innovation & Capital. © Modular Finance, source Nordic Press Releases